Investigating the role of active Rap1a binding IQGAP1 in choroidal neovascularization
研究活性 Rap1a 结合 IQGAP1 在脉络膜新生血管形成中的作用
基本信息
- 批准号:10513814
- 负责人:
- 金额:$ 3.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-30 至 2025-09-29
- 项目状态:未结题
- 来源:
- 关键词:AdultAdverse effectsAgeBindingBinding ProteinsBiological AssayBlindnessBlood VesselsChoroidChoroidal NeovascularizationClinicalCo-ImmunoprecipitationsCyclic AMPDevelopmentEndothelial CellsEndotheliumEventExudative age-related macular degenerationEyeFellowshipFlow CytometryGTP BindingGenerationsGoalsGrowthGrowth Factor InhibitionGuanosine Triphosphate PhosphohydrolasesHealthHomeostasisHumanIQ motif containing GTPase activating protein 1ImageImmunohistochemistryIn VitroIndividualKnockout MiceLaser injuryLasersLeadLectinLesionMediatingMethodsMigration AssayModelingMusNeural RetinaNeuronsOphthalmologyOptical Coherence TomographyPathogenesisPathologicPatientsPharmacologyPhysiciansPhysiologicalRegulationResearchRetinaRiskRoleScientistSignal TransductionStainsStructure of retinal pigment epitheliumTamoxifenTestingTherapeuticTrainingTransfectionTubeVascular Endothelial Growth FactorsVisionVisual AcuityWestern Blottingangiogenesiscell motilityimprovedinhibitorintravitreal injectionknock-downmatrigelmigrationmouse modelmutantneurosensorynovelpreventrelating to nervous systemrho GTP-Binding Proteinsstandard carestandard of caretargeted treatment
项目摘要
PROJECT SUMMARY
Neovascular age-related macular degeneration (nvAMD) is a leading cause of central vision loss in individuals
over the age of 50 years. Vision loss occurs when choroidal endothelial cells (CECs) transmigrate the retinal
pigment epithelium (RPE) into the neurosensory retina and form choroidal neovascularization (CNV). Current
standard of care includes agents that inhibit the bioactivity of vascular endothelial growth factor (VEGF).
Although anti-VEGF agents have reduced CNV and improved visual acuity in patients, there are concerns
about possible adverse effects on neuronal and glial health in the retina from long-term VEGF inhibition. Thus,
better understanding of downstream VEGF signaling in CECs is necessary to identify more targeted
therapeutic approaches. One of the downstream effectors is Rac1, a Rho GTPase that in the GTP-bound state
regulates CEC transmigration. VEGF-mediated Rac1GTP is sustained by binding IQ motif containing GTPase
activating protein 1 (IQGAP1), a multidomain GTPase-binding protein, at a specific domain. Therefore,
interfering with Rac1GTP/IQGAP1 binding may be an approach to inhibit CEC migration and prevent vision-
threatening CNV. Cultured CECs that express constitutively active Rap1a, a Ras GTPase that also binds to
IQGAP1, had reduced VEGF-mediated Rac1GTP and Rac1GTP/IQGAP1 interactions. Together, these results
suggest that increased Rap1aGTP/IQGAP1 binding in CECs reduces VEGF-induced Rac1GTP, CEC
migration and CNV by interfering with Rac1GTP/IQGAP1 binding. This proposal will determine the mechanistic
role of Rap1GTP binding the IQ domain of IQGAP1 on Rac1GTP/IQGAP1 interactions in Specific Aim 1 and in
vitro angiogenesis in Specific Aim 2. In Specific Aim 3, this proposal will determine the mechanistic role of
Rap1aGTP/IQGAP1 interactions in endothelial cells during CNV development. Methods include: isolation of
CECs from adult human donor eyes; transfection of CECs with mutant IQGAP1 constructs; pharmacologic
activation of Rac1 and Rap1; co-immunoprecipitation; western blot; Matrigel migration assay; tube formation
assay; proliferation assay; Rap1b null mice and tamoxifen-inducible endothelial-IQGAP1 knockout mice;
murine laser-induced CNV model; intravitreal injections of agents that activate Rap1; flow cytometry;
immunohistochemistry of RPE/choroid flat mounts and cryo-sections; Micron IV imaging; and spectral domain
optical coherence tomography. These studies will elucidate a potential mechanism of regulating
Rac1GTP/IQGAP1 interactions, which has an important role in VEGF-induced CEC migration and CNV
pathogenesis, and potentially identify targeted therapeutic approaches that can reduce risks from current
standard of care VEGF inhibitors. Furthermore, this fellowship application outlines a detailed research and
clinical training plan to help the candidate become a successful physician-scientist in ophthalmology.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Aniket Ramshekar其他文献
Aniket Ramshekar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Aniket Ramshekar', 18)}}的其他基金
Investigating the role of active Rap1a binding IQGAP1 in choroidal neovascularization
研究活性 Rap1a 结合 IQGAP1 在脉络膜新生血管形成中的作用
- 批准号:
10313201 - 财政年份:2021
- 资助金额:
$ 3.65万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 3.65万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 3.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 3.65万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 3.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 3.65万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 3.65万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 3.65万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 3.65万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 3.65万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 3.65万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




